Connection
Shmuel Yaccoby to Osteoclasts
This is a "connection" page, showing publications Shmuel Yaccoby has written about Osteoclasts.
|
|
Connection Strength |
|
|
|
|
|
2.614 |
|
|
|
-
Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013 Jun; 41(6):547-557.e2.
Score: 0.345
-
Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma. 2010 Feb; 51(2):213-20.
Score: 0.279
-
Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett. 2009 Nov 01; 284(2):175-81.
Score: 0.265
-
Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N, Yaccoby S. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol. 2009 Jun; 145(6):775-87.
Score: 0.264
-
Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2008 Feb; 22(2):406-13.
Score: 0.240
-
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 2006 Apr; 133(1):83-92.
Score: 0.214
-
Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res. 2005 Nov 01; 11(21):7599-606.
Score: 0.208
-
Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004 Mar 15; 64(6):2016-23.
Score: 0.186
-
Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002 Feb; 116(2):278-90.
Score: 0.160
-
Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer. 2015 Nov 06; 15:864.
Score: 0.104
-
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol. 2013 Jun; 88(6):463-71.
Score: 0.087
-
Li X, Ling W, Khan S, Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 2012 Aug; 27(8):1635-48.
Score: 0.083
-
Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010 May; 149(3):311-21.
Score: 0.070
-
Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009 Jan; 84(1):6-14.
Score: 0.065
-
Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010 Jan 07; 115(1):61-70.
Score: 0.017
-
Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007 May 15; 109(10):4470-7.
Score: 0.014
-
Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006 Sep; 7(2):109-14.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|